CSHP is the leading advocate, actively engaging policy makers and advancing the role of pharmacy professionals in all practice settings. Empower Pharmacists and Pharmacy …

Get informed on what screenings are necessary at each age. Why Vaccinate Against Measles? Measles cases are increasing across the country. The disease spreads quickly and can be …

Pharmacist Labor Projections, Definitions, and Future Needs. Session: Coming Soon to a Hospital Near You! - Challenges with Inpatient Administration of N-Acetylcysteine, Insulin, and …

Portal hypertension (PH) is defined as increased pressure in the portal venous system, which most often results from elevated intra­hepatic vascular resistance caused by cirrhosis. Advances in the field of PH have impacted 3 main areas.

Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated.

The following programs are participating in this year’s Residency & Fellowship Showcase (updated as of 10/1/2024). View all of our Student Programming here.

Portal hypertension (PH) is the most morbid complication of advanced liver disease (LD). Clinically significant portal hypertension (CSPH) is responsible for hepatic decompensation and results in significant morbidity and mortality.

2023年7月13日 · Clinically significant portal hypertension (CSPH) is a serious clinical condition causing decompensation and potentially fatal complications especially in the presence of advanced liver disease. This article aims to critically review the current literature on non-invasive assessment of CSPH.

2021年11月5日 · Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, represents a significant milestone in the natural history of chronic liver disease [1].

Among patients with compensated cirrhosis or compensated advanced chronic liver disease (cACLD – defined at the Baveno VI conference), the presence or absence of clinically significant portal hypertension (CSPH) is associated with differing outcomes, including risk of death, and different diagnostic and therapeutic needs.